ARS Pharmaceuticals, Inc.

NasdaqGM SPRY

ARS Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 0.00

ARS Pharmaceuticals, Inc. Total Non-Current Liabilities is USD 0.00 for the quarter ending September 30, 2024, a -100.00% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

ARS Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 92.00 K.
ARS Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 5.08 M.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqGM: SPRY

ARS Pharmaceuticals, Inc.

CEO	Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
IPO Date	Dec. 4, 2020
Location	United States
Headquarters	3525 Del Mar Heights Road
Employees	24
Sector	Health Care
Industries Pharmaceuticals

Description

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Key trends

Past 5 years